Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Preference for Monthly Ibandronate vs Weekly Risedronate in Postmenopausal Osteoporosis
NCT00377234Phase 4Completed
- Sponsor
- Roche
- Start
- May 2006
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ibandronate in postmenopausal osteoporosis (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants Who Preferred Ibandronate Monthly Dosing to Risedronate Weekly Dosing at 6 months. Started May 2006; status: completed.
02
Drugs
ibandronate
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00377234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00377234.